FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.
Lecanemab (marketed as Leqembi) is today’s top Alzheimer’s drug. Why does equitable access to this drug remain a significant challenge? What needs to be done?
MEDICATION VIDEO:
How do you know when Alzheimer’s meds ought to be stopped? Explore the benefits of these medications, such as improved cognition, memory, behavior, lifespan, and the stages they are most effective.
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?
See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
DEMENTIA & HOLIDAY PLANS: Relatives with dementia may be frail or have special emotional, mental and physical health needs. Check out these ways to help them enjoy the holiday season.
Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.
It is one of the most beautiful Compensations of this life thatNo man can sincerely try to help anotherWithout helping himself.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
No spam, only news and updates.
